Abstract
Get full access to this article
View all access options for this article.
References
1.
Deal value reflects only the six oncology targets among the eight additional targets BMS and CytomX agreed to add in 2017; the other two were to be in non-oncology indications. The value for all eight targets is $3.786 billion.